Pharmacogenetics of the Treatment Response of Age-Related Macular Degeneration with Ranibizumab and Bevacizumab

Author： Kanoff Justin   Miller Joan  

Publisher： Informa Healthcare

ISSN： 0882-0538

Source： Seminars in Ophthalmology, Vol.28, Iss.5-6, 2013-09, pp. : 355-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite

Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison

By  

Ophthalmologica, Vol. 232, Iss. 3, 2014-08 ,pp. : 149-155

Karger

Access to resources Recommend Favorite

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 231, Iss. 2, 2013-12 ,pp. : 80-85

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration

By  

Ophthalmic Research, Vol. 45, Iss. 3, 2010-09 ,pp. : 129-134

Karger

Access to resources Recommend Favorite

Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab

By  

Ophthalmologica, Vol. 225, Iss. 4, 2011-02 ,pp. : 211-221

Karger

Access to resources Recommend Favorite